1. Phase 1 study of DS‐1205c combined with gefitinib for EGFR mutation‐positive non‐small cell lung cancer
   Koichi Goto et al, 2023, Cancer Medicine CrossRef
2. A single cell RNAseq benchmark experiment embedding “controlled” cancer heterogeneity
   Maddalena Arigoni et al, 2024, Scientific Data CrossRef
3. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer
   G Sette et al, 2015, Cell Death & Disease CrossRef
4. An effective drug sensitizing agent increases gefitinib treatment by down regulating PI3K/Akt/mTOR pathway and up regulating autophagy in non-small cell lung cancer
   Jue Zhang et al, 2019, Biomedicine & Pharmacotherapy CrossRef
5. The evidence for repurposing anti-epileptic drugs to target cancer
   Mir Aroosa et al, 2023, Molecular Biology Reports CrossRef
6. The Redox-Active Manganese(III) Porphyrin, MnTnBuOE-2-PyP5+, Impairs the Migration and Invasion of Non-Small Cell Lung Cancer Cells, Either Alone or Combined with Cisplatin
   Rita B. Soares et al, 2023, Cancers CrossRef
7. Human Organ Chip Models Recapitulate Orthotopic Lung Cancer Growth, Therapeutic Responses, and Tumor Dormancy In Vitro
   Bryan A. Hassell et al, 2017, Cell Reports CrossRef
8. Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression
   Taeyoung Koo et al, 2017, Nucleic Acids Research CrossRef
9. Coins in microfluidics: From mere scale objects to font of inspiration for microchannel circuits
   Gabriele Pitingolo et al, 2019, Biomicrofluidics CrossRef
10. Yiqi Chutan Tang Reduces Gefitinib‐Induced Drug Resistance in Non‐Small‐Cell Lung Cancer by Targeting Apoptosis and Autophagy
    Jue Zhang et al, 2020, Cytometry Part A CrossRef
11. Phosphorylation of a Human Microprotein Promotes Dissociation of Biomolecular Condensates
    Zhenkun Na et al, 2021, Journal of the American Chemical Society CrossRef
12. Nanoparticle-mediated cancer cell therapy: basic science to clinical applications
    Jaya Verma et al, 2023, Cancer and Metastasis Reviews CrossRef
13. Cytosolic malic enzyme and glucose‐6‐phosphate dehydrogenase modulate redox balance in NSCLC with acquired drug resistance
    Maoxin Ran et al, 2023, The FEBS Journal CrossRef
14. Macrophage renewal modes affect acquired resistance to gefitinib in EGFR‑mutant lung cancer PC‑9 cells
    Baoxia Zhao et al, 2022, Oncology Reports CrossRef
15. Gel-based cell manipulation method for isolation and genotyping of single-adherent cells
    Ryo Negishi et al, 2019, The Analyst CrossRef
16. Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials
    Syed Nasir Abbas Bukhari, 2022, Pharmaceutics CrossRef
17. Regulation of EGFR signalling by palmitoylation and its role in tumorigenesis
    Yasmin A. Kadry et al, 2021, Open Biology CrossRef
18. Unveiling the altered metabolic pathways induced by nivolumab in non-small cell lung cancer via GC–MS metabolomics approach coupled with multivariate analysis
    Manal E. Alosaimi et al, 2024, Journal of Chromatography B CrossRef
19. Antitumor Activity of DFX117 by Dual Inhibition of c-Met and PI3Kα in Non-Small Cell Lung Cancer
    Yanhua Fan et al, 2019, Cancers CrossRef
20. Rapid detection and genotyping of ALK fusion variants by adapter multiplex PCR and high-resolution melting analysis
    Mei Li et al, 2020, Laboratory Investigation CrossRef
21. Drug resistance in cancer: mechanisms and tackling strategies
    Tanweer Haider et al, 2020, Pharmacological Reports CrossRef
22. MnTnHex-2-PyP5+ Displays Anticancer Properties and Enhances Cisplatin Effects in Non-Small Cell Lung Cancer Cells
    Rita Soares et al, 2022, Antioxidants CrossRef
23. The Diagnostic Value of ACSL1, ACSL4, and ACSL5 and the Clinical Potential of an ACSL Inhibitor in Non-Small-Cell Lung Cancer
    Yunxia Ma et al, 2024, Cancers CrossRef